Grey Matters Health Inc.

04/01/2024

🔬AI's Impact on Drug Discovery

Traditional drug discovery can be a long and expensive process, with low success rates. Advanced machine learning is transforming the field. By analyzing extensive biological and clinical data, it predicts drug interactions, adverse effects, and uncovers repurposing opportunities.

Read more on these advancements!

An artificial intelligence framework could push the boundaries of drug discovery by rapidly revealing new clinical indications for pre-existing drugs.

03/04/2024

Due to the limited efficacy of traditional treatments for chronic disability following traumatic brain injury (TBI), the emergence of ibogaine, a novel psychedelic substance, shows promise in managing these conditions.

In a study of 30 male US military veterans with TBI, 83% experienced improvements in mental health, processing speed, problem-solving, and working memory.

Read more on this here ⬇️

Military veterans with traumatic brain injury saw drastic reductions in depression and symptoms of post-traumatic stress disorder after using the psychedelic drug ibogaine

02/12/2024

We are pleased to announce the receipt of a notice of allowance from the Japanese Patent Office titled: 'Compositions and Methods for Treating Idiopathic Pulmonary Fibrosis (IPF).'

Check out what our CEO says about this great development ➡️ https://bit.ly/3tXUQws

02/06/2024

: Ifenprodil is a targeted NMDA receptor antagonist, specifically focusing on GluN2B. The NMDA receptor is present in various tissues, including lung cells, T-cells, neutrophils, and certain types of cancer cells.

🧬Algernon has been granted a notice of allowance for the patent application aimed at treating Idiopathic Pulmonary Fibrosis with Ifenprodil. By repurposing this drug, they aspire to address not only IPF but also interstitial lung disease.

Get more details here ➡️ https://bit.ly/3tXUQws

02/01/2024

Artificial intelligence and machine learning (AI/ML) are transforming pharmaceutical research, transforming drug discovery, repurposing, clinical testing, and productivity.

Algernon focuses on the drug repurposing model to provide a cost-effective and capital-efficient way to discover new uses for drugs.

Learn more about how AI is revolutionizing this industry! ➡️

Artificial intelligence and machine learning will revolutionize pharmaceutical research including clinical trials

01/31/2024

NEWS RELEASE: We are pleased to report that Algernon (CSE: AGN | FRANKFURT: AGW | OTCQB: AGNPF) has received a notice of intention to grant from the Chinese Patent Office for its anti-fibrotic drug candidate NP-251 (Repirinast).

Repirinast is Algernon’s leading candidate for the treatment of renal fibrosis and kidney disease, and will be the company’s second patented medication in China.

Check out the full press release 👉 https://bit.ly/3OlZMSX